$4.47 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 122 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BDSI | Exit | BIODELIVERY SCIENCES INTL IN | $0 | – | -29,204 | -100.0% | -0.00% | – |
| WVE | Exit | WAVE LIFE SCIENCES LTD | $0 | – | -552,690 | -100.0% | -0.04% | – |
| Exit | PYXIS ONCOLOGY INC | $0 | – | -311,754 | -100.0% | -0.07% | – | |
| Exit | DEFINITIVE HEALTHCARE CORP | $0 | – | -250,000 | -100.0% | -0.14% | – | |
| Exit | HYPERFINE INC | $0 | – | -1,000,000 | -100.0% | -0.15% | – | |
| PRVA | Exit | PRIVIA HEALTH GROUP INC | $0 | – | -300,000 | -100.0% | -0.16% | – |
| Exit | GUARDANT HEALTH INCnote 11/1 | $0 | – | -8,000,000 | -100.0% | -0.17% | – | |
| Exit | WEAVE COMMUNICATIONS INC | $0 | – | -554,519 | -100.0% | -0.18% | – | |
| Exit | LIANBIOsponsored ads | $0 | – | -1,782,747 | -100.0% | -0.23% | – | |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -110,000 | -100.0% | -0.25% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -141,000 | -100.0% | -0.27% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -343,213 | -100.0% | -0.34% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INCcall | $0 | – | -1,000,000 | -100.0% | -0.35% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -216,000 | -100.0% | -0.37% | – |
| FIGS | Exit | FIGS INCcl a | $0 | – | -829,707 | -100.0% | -0.48% | – |
| VIVO | Exit | MERIDIAN BIOSCIENCE INC | $0 | – | -1,125,083 | -100.0% | -0.48% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -5,000,000 | -100.0% | -0.52% | – |
| PCRX | Exit | PACIRA BIOSCIENCES INC | $0 | – | -596,338 | -100.0% | -0.75% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -1,172,943 | -100.0% | -0.84% | – |
| APR | Exit | APRIA INC | $0 | – | -1,655,795 | -100.0% | -1.13% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.